Background and Objectives. Bilateral knee osteoarthritis (KOA) in older patients compromises mobility and quality of life. Gait analysis provides objective, reproducible measures of physical performance. This study evaluated the integration of gait analysis for longitudinal monitoring and personalized rehabilitation, while ultrasound was performed only at baseline for characterization and did not inform adjustments to the interventions. Materials and Methods. We conducted a 6-week, randomized, parallel-group clinical trial including 130 participants aged ≥65 years. Patients were randomized to a Study Group (SG, n = 64) receiving 10 sessions of a comprehensive rehabilitation program (conventional measures plus gait training) or a Control Group (CG, n = 66) receiving 10 sessions of conventional rehabilitation (electrotherapy with magnetodiaflux, TENS, therapeutic ultrasound, low-intensity laser, plus standard kinesitherapy). Interventions were delivered daily, 5 days/week, over 2 consecutive weeks. Gait outcomes (BTS G-WALK/G-SENSOR 2) included TUG, Symmetry Index, 6MWD, and cadence; functional outcomes included VAS pain, WOMAC, and Lequesne Index. Quadriceps morphology was assessed sonographically, and a height-normalized quadriceps thickness index (QHNI) was calculated. Results. Of 130 randomized, 112 completed (93.3%). Compared with control, the intervention produced significant, clinically meaningful improvements: 6MWD increased by approximately 59 m, cadence by ~9 steps/min; TUG improved by ~2.6 s; gait symmetry by ~4–5 points; VAS pain decreased by ~1.7 points; WOMAC total by ~8.5 points; and Lequesne Index by ~2 points (all p < 0.001). QHNI showed no significant association with anthropometrics and performance measures, indicating limited value as a linear predictor at baseline; nonlinear models or subgroup analyses may be warranted. Conclusions. Both neuromuscular-focused rehabilitation and the conventional program improved gait and clinical outcomes. Integrating gait analysis with ultrasound evaluation enables comprehensive monitoring and supports personalized interventions to reduce joint loading and optimize gait mechanics in older patients with bilateral KOA.

Background: During the SARS-CoV-2 pandemic period, in the treatment approved by the WHO, along with antivirals, antibiotics, nonsteroidal anti-inflammatory drugs and anticoagulants, dexamethasone was always used. This study started from the professional concern related to the vasopressor effect of cortisone on blood pressure (BP). Methods: The study group was achieved by selecting, from a total of 356 patients hospitalized in the clinic, the patients with known hypertensive status at admission for SARS-CoV-2. Dexamethasone was part of the anti-COVID-19 treatment, with an administration of 4–6–8 mg/day, depending on bodyweight, for 10 days. All patients with hypertension received antihypertensive treatment in adjusted doses according to the recorded BP values. Results: Monitoring of BP in hospitalized patients was performed daily, in the morning and evening. If on the 2nd day of treatment, 84% of the patients partially responded to the treatment with a moderate decrease in BP, on the 3rd therapy day, the situation clearly improved: more than 75% of the patients had values of BP that can be classified as high-normal (38.23%) and normal (40.03%). Conclusions: Dexamethasone for treatment of SARS-CoV-2 infection did not have a notable influence on increasing BP, because the doses were low–moderate and prescribed for a short time.

Chronic cervical radiculopathy (CR) is a common cause of pain and disability in adults. The primary objective of our study was to evaluate the efficacy of a structured, multimodal rehabilitation program, with or without adjunct neurotrophic supplementation, in chronic cervical radiculopathy; secondarily, this study investigates which patients are most likely to benefit from neurotrophic supplementation and aims to assess effects on pain, cervical mobility, disability, and daily activities to guide individualized care. Patients and Methods: In this prospective, randomized controlled trial, 82 patients with chronic CR were allocated to a study group (SG, n = 42) receiving a three-month multimodal rehabilitation program plus daily neurotrophic supplementation (named PHSD) or a control group (CG, n = 40) receiving the same rehabilitation alone. Outcome measures included the Visual Analogue Scale (VAS), Neck Disability Index (NDI), cervical mobility indexes (CSI—Chin-Sternum Index; OWI—Occiput-Wall Index; TAI—Tragus-Acromion Index), and Katz ADL (Activity of Daily Living) Index, assessed at baseline and after three months. Results: Both groups showed significant improvements, but the SG demonstrated greater reductions in pain (median VAS change: 8.16 ± 0.72 vs. 5.11 ± 0.70, p < 0.001) and disability (mean NDI change: 24.71 ± 5.13 vs. 20.90 ± 4.49, p < 0.001). Cervical mobility indexes improved in both groups, with larger gains in the SG (p < 0.01), supporting the potential benefits of adding neurotrophic supplementation. Conclusions: A structured multimodal rehabilitation program significantly improves pain, mobility, and disability in chronic CR, while combining it with PHSD may enhance these effects. Further randomized trials are needed to confirm these findings and establish standardized conservative treatment protocols.

Postbiotics are defined as preparations of inanimate microorganisms and/or their components that confer a health benefit on the host. Although interest in postbiotics has increased substantially, their translational use in functional foods remains insufficiently characterized with respect to preparation identity, production methodology, food-matrix compatibility, mechanistic specificity, and regulatory positioning. This PRISMA-guided structured review aims to synthesize current evidence on postbiotics in functional food and nutraceutical contexts, with particular emphasis on preparation-based characterization, gut–brain axis-related mechanisms and clinical findings, food matrix applicability, and regulatory and health-claim considerations. Unlike broader postbiotic reviews that mainly address definitions, general health effects, or technological stability, this review integrates preparation identity, production process, gut–brain axis-related evidence, food matrix compatibility, and regulatory/health-claim translation within a single functional food framework. A structured literature search was conducted in Scopus and Web of Science Core Collection and was completed on 16 February 2026. The search strategy included three conceptual blocks: postbiotic and inactivation-based preparation terms, functional food/nutraceutical and food matrix terms, and gut–brain axis-related clinical and mechanistic terms. Cosmetic, topical, veterinary, animal feed, and aquaculture-focused publications were excluded. The export files contained 131 records from Scopus and 136 from the Web of Science Core Collection, yielding 267 records after applying document-type and language filters. After manually removing duplicates, 237 unique records were screened. Following title/abstract screening, 176 records were excluded as outside the scope of the review, and 61 publications were retained for full-text assessment and final thematic synthesis. The review was reported according to applicable PRISMA 2020 items. The evidence was organized into three thematic domains: gut–brain axis-related clinical findings, mechanistic evidence, and food matrix/product development applications. Heat-inactivated preparations, including Lactobacillus gasseri CP2305 and Lactiplantibacillus plantarum SNK12, have shown preliminary effects on stress-related symptoms, sleep quality, and selected neuroendocrine or inflammatory biomarkers in human studies. Mechanistic pathways include gut barrier integrity, immunomodulation, short-chain fatty acid signaling, tryptophan–kynurenine–serotonin metabolism, vagal communication, and regulation of the hypothalamic–pituitary–adrenal axis. Food matrix studies support the potential application of postbiotics in fermented dairy products, cereal-based systems, plant-based matrices, powders, concentrates, and bioactive packaging; however, matrix-dependent effects on bioavailability, sensory quality, and biological activity remain incompletely defined. Postbiotics provide a stable translational platform for functional-food development, but their scientific and commercial use requires clear characterization of the microbial source, production process, inactivation method, retained active fractions, dose metric, delivery matrix, and clinically meaningful endpoint. Future studies should avoid broad category-level claims and prioritize preparation- and matrix-defined human evidence with standardized safety reporting.

Diabetes mellitus represents a major global health burden, necessitating the development of safer and more effective therapeutic alternatives. Medicinal plants have gained increasing attention due to their bioactive compounds with potential hypoglycemic and antioxidant effects. The present study aimed to investigate the physicochemical characteristics, phytochemical composition, antioxidant capacity, and toxicological profile of hydroalcoholic tinctures obtained from Agrimonia pilosa Ledeb., Calendula arvensis L., and Polygonum hydropiper L. The tinctures were prepared by simple percolation using 70% ethanol and evaluated according to pharmacopoeial standards, including organoleptic properties, relative density, refractive index, alcohol content, and purity parameters. Phytochemical analysis was performed using thin-layer chromatography and spectrophotometric methods, highlighting the presence of flavonoids and polyphenolcarboxylic acids, with several bands showing chromatographic and spectral similarities to chlorogenic and caffeic acid standards. Antioxidant activity was assessed through total polyphenol and flavonoid content, with Polygonum hydropiper exhibiting the highest values. The hypoglycemic effect was evaluated using the oral glucose tolerance test in normoglycemic mice, demonstrating significant reductions in blood glucose levels, particularly for Agrimonia pilosa at higher doses. Acute toxicity studies indicated a low toxicity profile, with no mortality observed even at high doses (up to 9 g/kg body weight), corresponding to GHS category 5. However, subacute toxicity assessment revealed species-dependent effects, ranging from minimal hepatic changes for Calendula arvensis to moderate hepatotoxicity for Polygonum hydropiper and more pronounced hepatic, renal, and pancreatic alterations for Agrimonia pilosa. These findings suggest that the investigated tinctures possess significant hypoglycemic and antioxidant potential, with generally favorable safety profiles following acute administration. Nevertheless, prolonged use may induce organ-specific toxicity, highlighting the need for further pharmacological and clinical investigations to establish their therapeutic applicability and safety in diabetes management.

Postprandial hyperglycemia can be modified before absorbed glucose reaches the circulation. Plant-derived compounds may slow starch hydrolysis through α-amylase and intestinal α-glucosidases, stimulate glucagon-like peptide-1 (GLP-1) release, or preserve incretin activity through dipeptidyl peptidase-4 (DPP-4) inhibition. This critical narrative review integrates these mechanisms around intestinal exposure, substrate selectivity, and human evidence. Flavonoids show structure-dependent and time-dependent inhibition of carbohydrate-hydrolyzing enzymes, but results vary markedly between yeast, rodent, and human enzyme systems. Iminosugar-rich mulberry preparations and thiosugar-containing Salacia extracts provide the strongest chemistry-to-clinic examples, including randomized trials that reduced postprandial glucose or HbA1c. Preclinical studies suggest that berberine may link bitter-taste-receptor-mediated GLP-1 secretion with local intestinal DPP-4 effects, whereas mangiferin, flavonol glycosides, anthocyanins, and food-derived peptides remain supported mainly by preclinical studies. In vitro potency alone is insufficient: meal composition, enzyme source, luminal concentration, metabolism, product standardization, gastrointestinal tolerance, and incretin measurements determine translational value. Candidate prioritization requires defined chemistry, achievable exposure, and product-specific human validation; acute effects do not establish durable benefit or human target engagement.